 Biofrontera AG NASDAQ: BFRA; Frankfurt Stock Exchange: B8F the Company, an international biopharmaceutical company, announced today that it has adopted comprehensive measures to reduce costs during the global COVID-19 pandemic. Biofrontera management anticipates declining demand for its product Ameluz due to current measures and regulations implemented by governments worldwide in an attempt to control the COVID-19 pandemic. As such, the company must be prepared for a transiently declining global demand for Biofronteras products due to the Coronavirus pandemic. 